NCT03396419

Brief Summary

The purpose of the ImpACT-24col sub-study is to explore effect of SPG stimulation on the augmentation of collateral blood flow and to relate it to the subject's cerebral blood flow status, the extent of the collateral vessel potency prior to the stimulation and the relation of the vessel occlusion site to the vasodilatory effect by using digital subtraction angiography (DSA), the gold standard imaging technique to demonstrate collateral blood flow dynamics. The results of this study will further promote the knowledge towards optimization of SPG stimulation to treat acute ischemic stroke patients.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2017

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 25, 2017

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

September 27, 2017

Completed
4 months until next milestone

First Posted

Study publicly available on registry

January 11, 2018

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 3, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 3, 2018

Completed
Last Updated

April 24, 2019

Status Verified

April 1, 2019

Enrollment Period

8 months

First QC Date

September 27, 2017

Last Update Submit

April 23, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Collateral blood flow grades difference following SPG stimulation.

    The difference between the collateral blood flow grades, assessed by DSA, at baseline and following SPG stimulation.

    Day 1

Study Arms (1)

Acute Isch. Stk pts treat. w/SPG stimul.

Following implantation (according to the ImpACT-24B protocol), subjects will be transferred to the angio suite. A baseline brain digital subtraction angiography (DSA) will then be performed by a trained physician prior to initiation of SPG stimulation according to the ImpACT-24B protocol. Following the first SPG stimulation cycle of 4 minutes, a post-stimulation DSA will be performed. Based on the results of the post-stimulation DSA, the physician may perform an additional DSA following the second SPG stimulation cycle. The subject will then be transferred to the stroke department and will continue treatment according the ImpACT-24B protocol.

Eligibility Criteria

Age40 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects with Acute Ischemic Stroke in the anterior circulation enrolled to the ImpACT-24B study.

You may not qualify if:

  • Additionally, subjects will be excluded from the ImpACT-24col sub-study if DSA is contraindicated (such as allergy to the contract media, etc.).
  • Age: Between 40 years and 80 years for male and 85 for female subjects
  • Clinical diagnosis of an acute ischemic stroke in the Carotid, Middle or Anterior Cerebral Artery territories
  • Imaging findings demonstrating signs of ischemia in the anterior circulation, consistent with the clinical diagnosis
  • Baseline NIHSS ≥ 7 and ≤ 18 within 2 hours prior to implantation.
  • Ability to initiate treatment within 8- 24 hours from stroke onset
  • Signed informed consent from patient him/herself or legally authorized representative if applicable
  • Intracranial hemorrhage or hemorrhagic transformation
  • Massive stroke
  • Acute ischemic stroke in the posterior circulation
  • Minor stroke
  • Treated with IV-tPA ,IA-tPA or neurothrombectomy devices for the current stroke
  • Previous stroke in the last 6 months or pre-existing disability
  • Patients with bleeding propensity or any condition in the oral cavity that prevents implantation
  • Clinical signs and symptoms or imaging evidence of bilateral stroke.
  • +8 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

High Technology Medical Center University Clinic LTD.

Tbilisi, 0144, Georgia

Location

MeSH Terms

Conditions

Ischemic Stroke

Condition Hierarchy (Ancestors)

StrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Yoram Slolberg, Dr.

    BrainsGate

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 27, 2017

First Posted

January 11, 2018

Study Start

September 25, 2017

Primary Completion

June 3, 2018

Study Completion

June 3, 2018

Last Updated

April 24, 2019

Record last verified: 2019-04

Locations